Cargando…

Met in lung cancer

Receptor tyrosine kinases play important roles in the biology of many tumor cell types. In approximately 10% of non-small cell lung cancer (NSCLC) patients mutational activation of the epidermal growth factor receptor (EGFR) results in tumor cells that are exquisitely addicted to signaling by this r...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049779/ https://www.ncbi.nlm.nih.gov/pubmed/24618893 http://dx.doi.org/10.4161/cbt.28504

Ejemplares similares

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

Multi-kinase inhibition in ovarian cancer
por: Dent, Paul
Publicado: (2014)

FADD the bad in head and neck cancer
por: Dent, Paul
Publicado: (2013)

Multi-kinase modulation for colon cancer therapy
por: Dent, Paul
Publicado: (2013)

The multi-hit hypothesis in basal-like breast cancer
por: Dent, Paul
Publicado: (2013)

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
por: Kujtan, Lara, et al.
Publicado: (2023)

Crosstalk between ERK, AKT, and cell survival
por: Dent, Paul
Publicado: (2014)

New methods to control neuroblastoma growth
por: Dent, Paul
Publicado: (2014)

Not so WEE: Targeting G(2)/M to kill mesothelioma cells
por: Dent, Paul
Publicado: (2014)

ERK plays the baddie (again)
por: Dent, Paul
Publicado: (2013)

Arsenic in leukemia: A RSKy business
por: Dent, Paul
Publicado: (2013)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

Janus-faced Kupffer cells in tumor metastasis
por: Dent, Paul
Publicado: (2013)

Non-canonical p53 signaling to promote invasion
por: Dent, Paul
Publicado: (2013)

Ceramide in the prostate
por: Dent, Paul
Publicado: (2013)

The flip side of doxorubicin: Inflammatory and tumor promoting cytokines
por: Dent, Paul
Publicado: (2013)

HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013)

Deceased donor transplantation in India: How the challenges are being met?
por: Parthasarathy, R., et al.
Publicado: (2017)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

Introduction of a rapid response system: why we are glad we MET
por: Jones, Daryl, et al.
Publicado: (2006)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion
por: Smith Gueye, Cara, et al.
Publicado: (2014)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

New method for discrimination of multiple primary lung cancer and metastatic lung cancer
por: Shen, Cheng, et al.
Publicado: (2022)

Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer
por: Basu Roy, Upal, et al.
Publicado: (2021)

Diagnosis and staging of lung cancer using transesophageal ultrasound: Training and assessment
por: Cold, Kristoffer Mazanti, et al.
Publicado: (2022)

Overview of Molecular Detection Technologies for MET in Lung Cancer
por: Heydt, Carina, et al.
Publicado: (2023)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Lung cancer screening—Marching along …
por: Fong, Kwun M., et al.
Publicado: (2022)

ALKing the flames of lung cancer immunosensitivity
por: Bayliss, Richard, et al.
Publicado: (2023)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uke0ks34nifu3kri2ljdo0q0n5